Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation

Clinical Nephrology

Volumn 75, Issue 1, 2011, Pages 16-25

  Kahraman, A ^a   Witzke, O ^a   Scherag, A ^a   Putter C ^a   Miller, M ^a   Dechene A ^a   Ross, S R ^a   Gerken, G ^a   Hilgard, P ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Academic Teaching Hospital EVK   (Germany)

Author keywords

Calcineurin inhibitor; Hepatitis C; Liver fibrosis; Renal transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN A; PREDNISOLONE; TACROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; CALCINEURIN; CYCLOSPORINE; FEMALE; GERMANY; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TACROLIMUS; TIME FACTORS; TRANSAMINASES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 79251548636     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CNP75016     Document Type: Article

References (50)

1. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998; 53: 1374-1381.
2. Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, Lunghi G et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation. 2005; 79: 1132-1136. (Pubitemid 40664010)
3. Natov SN, Lau JY, Ruthazer R, Schmid CH, Levey AS, Pereira BJ. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1999; 56: 700-706.
4. Fabrizi F, Bromberg J, Elli A, Dixit V, Martin P. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. Aliment Pharmacol Ther. 2005; 22: 657-666. (Pubitemid 41475328)
5. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time on renal-replacement therapy, and outcome after kidney transplantation. Transplantation. 2004; 78: 745-750.
6. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002; 36: 3-10.
7. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int. 1997; 52: 843-861.
8. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999; 29: 257-263.
9. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Jr., Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation. 1999; 67: 272-275.
10. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997; 51: 981-999.
11. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74: 427-437.
12. Giordano HM, Franca AV, Meirelles L, Escanhoela CA, Nishimura NF, Santos RL, Quadros KR et al. Chronic liver disease in kidney recipients with hepatitis C virus infection. Clin Transplant. 2003; 17: 195-199.
13. Chan TM, Lok AS, Cheng IK, Chan RT. Aprospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology. 1993; 104: 862-868.
14. Marcellin P, Martinot M, Boyer N, Levy S. Treatment of hepatitis C patients with normal aminotransferases levels. Clin Liver Dis. 1999; 3: 843-853.
15. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 1994; 107: 196-199.
16. Lorber MI. The mechanism of ciclosporin immunosuppression. Year Immunol. 1989; 4: 253-263.
17. Cristillo AD, Macri MJ, Bierer BE. Differential chemokine expression profiles in human peripheral blood T lymphocytes: dependence on T-cell coreceptor and calcineurin signaling. Blood. 2003; 101: 216-225.
18. Yin M, Ochs RS. Mechanism for the paradoxical inhibition and stimulation of calcineurin by the immunosuppresive drug tacrolimus (FK506). Arch Biochem Biophys. 2003; 419: 207-213.
19. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, Pinna AD et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 1998; 65: 1044-1046. (Pubitemid 28208421)
20. Hilgard P, Kahraman A, Lehmann N, Seltmann C, Beckebaum S, Ross RS, Baba HA et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol. 2006; 12: 697-702.
21. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int. 2009; 22: 49-60.
22. Nanmoku K, Imaizumi R, Tojimbara T, Nakajima I, Fuchinoue S, Sakamoto N, Watanabe M et al. Effects of immunosuppressants on the progression of hepatitis Cin hepatitis Cvirus-positive renal transplantation and the usefulness of interferon therapy. Transplant Proc. 2008; 40: 2382-2385.
23. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation. 2006; 82: 853-856.
24. Kamar N, Selves J, Sandres-Saune K, Durand D, Izopet J, Rostaing L. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? Transplant Proc. 2006; 38: 1329-1332.
25. Minz M, Sharma A, Das A, Chawla Y. Impact of anti-hepatitis C virus (HCV) antibody on outcomes in renal transplant recipients infected with HCV. Transplant Proc. 2008; 40: 2386-2388.
26. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang. 1999; 76: 149-158.
27. Jorgensen PA, Neuwald PD. Standardized hepatitis C virus RNA panels for nucleic acid testing assays. J Clin Virol. 2001; 20: 35-40.
28. Ross RS, Viazov S, Sarr S, Hoffmann S, Kramer A, Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods. 2002; 101: 159-168.
29. Castera L. Use of elastometry (FibroScan) for the non-invasive staging of liver fibrosis. Gastroenterol Clin Biol. 2007; 31: 524-530; quiz 500, 531-522.
30. Mendoza J, Gomez-Dominguez E, Moreno-Otero R. Transient elastography (Fibroscan), a new noninvasive method to evaluate hepatic fibrosis. Med Clin (Barc). 2006; 126: 220-222.
31. Balla A, Chobanian M. New-onset diabetes after transplantation: a review of recent literature. Curr Opin Organ Transplant. 2009; 14: 375-379.
32. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. Jama. 1993; 270: 1339-1343.
33. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant. 2004; 19 (Suppl) 3: 72-76.
34. Hanafusa T, Ichikawa Y, Yazawa K, Kishikawa H, Fukunishi T, Kanai T, Shinji Y et al. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc. 1998; 30: 122-124.
35. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001; 72: 241-244.
36. Teixeira R, Papatheodoridis GV, Burroughs AK. Management of recurrent hepatitis C after liver transplantation. J Viral Hepat. 2001; 8: 159-168.
37. Berenguer M. Management of hepatitis C virus in the transplant patient. Clin Liver Dis. 2007; 11: 355-376.
38. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and post-transplantation treatment. Clin J Am Soc Nephrol. 2007; 2: 563-575.
39. Pollard S. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Liver Int. 2004; 24: 402-406.
40. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis. 2001; 38: 919-934. (Pubitemid 33022168)
41. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001; 16: 1669-1674.
42. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 2007; 13: 975-983.
43. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation. 2005; 80: 1550-1555.
44. Alric L, Kamar N, Bonnet D, Danjoux M, Abravanel F, Lauwers-Cances V, Rostaing L. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transpl Int . 2009; 22: 568-573.
45. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol. 2008; 22: 991-1008.
46. Kew M, Francois G, Lavanchy D, Margolis H, Van Damme P, Grob P, Hallauer J et al. Prevention of hepatitis C virus infection. J Viral Hepat. 2004; 11: 198-205.
47. Lavanchy D, Gavinio P. Hepatitis C. Can J Gastroenterol. 2000; 14 (Suppl): 67-76.
48. Lamproye A, Belaiche J, Delwaide J. The FibroScan: a new non invasive method of liver fibrosis evaluation. Rev Med Liege. 2007; 62: 68-72.
49. Perez RM, Ferraz ML, Figueiredo MS, Contado D, Koide S, Ferreira AP, Cendoroglo Neto M et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol. 2003; 69: 489-494.
50. Lemos LB, Perez RM, Lemos MM, Draibe SA, Silva IS, Silva AE, Ferraz ML. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients. Nephron Clin Pract. 2008; 108: 135-140.